EMILY GOODLETT: Open Payments
NPI 1730521436 · FRANKFORT, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$951 in 55 payments from 15 companies in 2025. Trend: 2023 $1,409 · 2024 $950 · 2025 $951
Food & beverage: $951
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $458 |
| AstraZeneca Pharmaceuticals LP | 5 | $89 |
| Lilly USA, LLC | 4 | $71 |
| Amgen Inc. | 4 | $58 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| Novo Nordisk Inc | 2 | $34 |
| Teva Pharmaceuticals USA, Inc. | 1 | $32 |
| Alkermes, Inc. | 1 | $31 |
| GlaxoSmithKline, LLC. | 1 | $26 |
| Lundbeck LLC | 1 | $20 |
Products named: VRAYLAR, QULIPTA, AIRSUPRA, OTEZLA, CAPLYTA, JARDIANCE, AUSTEDO XR, LYBALVI.
Industry payments across KY — which companies pay providers there.
